This is a preview of subscription content, log in via an institution to check access.
References
Niiyama K, Hayama T, Mase T, et al. Discovery of J-104132, a potent, orally active, the most balanced ET(A)/ET(B) dual endothelin receptor antagonist [abstract]. 216th National Meeting of the American Chemical Society; Pt 2. 1998 Aug 23–27; Boston
Niiyama K, Hayama T, Mase T, et al. A potent, orally active, most balanced ET(A)/ET(B) dual endothelin receptor antagonist. Discovery of J-104132. 15th European Federation of Medical Chemistry (EFMC) International Symposium on Medicinal Chemistry; 1998 Sep 6–10; Edinburgh, 297
Shen Y-T, Buie P, Moussa T, et al. Chronic therapy with L- 753,037, and ET(A/B) receptor antagonist, in conscious dogs during development of heart failure. Circulation 1998 Oct 27; 98 Suppl.: 578
Nishikibe M, Ishikawa K, Fukuroda T, et al. Pharmacology of J-104,132, a potent, orally-active, mixed ET(A)/ET(B) endothelin receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 No. 1 (2 Suppl.): 511
Gabel R, Zingaro G, Nishikibe M, et al. Antihypertensive efficacy of J-104,132 (L-753,037), a potent, orally-active, mixed ET(A)/ET(B) endothelin receptor antagonist, in conscious, DOCA/salt hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 No. 1 (1 Suppl.): 269
Rights and permissions
About this article
Cite this article
J 104132. Drugs R&D 2, 26–27 (1999). https://doi.org/10.2165/00126839-199902010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902010-00006